Lexaria Bioscience Corp. (NASDAQ: LEXX) Developing A Powerful Technology To Treat Hypertension

This section is Partnership content provided

The content in this section is provided by GlobeNewswire for the purpose of distributing press releases on behalf of its clients. Postmedia has not reviewed the content.

for GlobeNewswire

GlobeNewswire

NEW YORK, Aug. 9, 2022 (GLOBE NEWSWIRE) — via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of more than 50 trusted brands of InvestorBrandNetwork (“IBN”), a multifaceted financial news and publication company for private and public entities.

To view the full post, “The Power of Science to Stop a Killer,” visit:

Almost half of American adults suffer from hypertension (high blood pressure), often called the silent killer. More than 114 million adults in this country are at risk of damage from the long-term force of blood pounding against artery walls, often leading to disease and death. The good news is that hypertension is treatable and manageable through lifestyle changes and medications. The fact is, there are several approved blood pressure medications on the market, but only about one in five people diagnosed with hypertension take medication. Why so few? Unfortunately, the side effects of these medications often outweigh the benefits.

This ad has not yet loaded, but your article continues below.

However, a new hypertension breakthrough may be imminent. A safer and better tolerated drug candidate has just marked a major milestone on the road to approval and commercialization. A global innovator in drug delivery platforms, Lexaria Bioscience Corp. (NASDAQ: LEXX) has quietly progressed through clinical trials and accumulated a growing body of evidence that strongly supports the use of its patented DehydraTECH(TM) technology in the therapy of hypertension.

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), enhances the way active pharmaceutical ingredients (“APIs”) enter the bloodstream promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids and nicotine up to five to ten times, reduce onset time from one to two hours to minutes, and mask unwanted tastes; the innovative technology is also being evaluated for orally administered antiviral drugs, nonsteroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors, and more. DehydraTECH has also demonstrated the ability to deliver some drugs more effectively across the blood-brain barrier. Lexaria operates an in-house licensed research laboratory and has a strong intellectual property portfolio with 25 granted patents and more than 50 patents pending worldwide.

This ad has not yet loaded, but your article continues below.

For more information about the company, visit a www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates related to LEXX are available from the company newsroom at https://ibn.fm/LEXX

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks summarizing corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full range of corporate communication solutions. As a multi-faceted financial news and content distribution company with a broad team of journalists and contributing writers, NNW is uniquely positioned to better serve private and public companies that wish to reach a broad audience of investors, consumers, journalists and general public. NNW has an ever-growing distribution network of over 5,000 key retail outlets across the country. By reducing information overload in today’s market, NNW provides its clients with unparalleled visibility, recognition and brand awareness.

NNW is where news, content and information come together.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (US cell phones only)
For more information, visit

Please see the full terms of use and disclaimers on the NetworkNewsWire website that apply to all content provided by NNW, whenever published or republished:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of InvestorBrandNetwork

This ad has not yet loaded, but your article continues below.

By clicking the signup button, you agree to receive the above newsletter from Postmedia Network Inc. You can unsubscribe at any time by clicking the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300

Thanks for signing up!

Postmedia is committed to maintaining a lively but civil discussion forum and encouraging all readers to share their views on our articles. Comments may take up to an hour to be moderated before appearing on the site. Please keep your comments relevant and respectful. We’ve enabled email notifications: You’ll now receive an email if you get a reply to your comment, there’s an update to a comment thread you follow, or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust yours e-mail configurations

[ad_2]

Source link